this is very significant as stated an unmet need and 100% tumour regression in the biggest fastest cancer killer, fastrack status for both drugs through the fda is a gimme imo these two drugs will be wanted by big Pharmas for sure licence agreements will be readily found and soon I expect, especially for dep/dox zlready in phase2
